Abstract:Besides their well-established roles in dietary lipid absorption and cholesterol homeostasis, bile acids (BA) also act as metabolically active signaling molecules. The flux of reabsorbed BA undergoing enterohepatic circulation, arriving in the liver with the co-absorbed nutrients (e.g. glucose, lipids), provides a signal that coordinates hepatic triglyceride (TG), glucose and energy homeostasis. As signaling molecules with systemic endocrine functions, BA can activate protein kinases A and C as well as mitogen-activated protein kinase pathways. Additionally, they are ligands for a G-protein-coupled BA receptor (TGR5/Gpbar-1) and activate nuclear receptors such as farnesoid X receptor (FXR; NR1H4). FXR and its downstream targets play a key role in the control of hepatic de novo lipogenesis, very-low-density lipoprotein-TG export and plasma TG turnover. BA-activated FXR and signal transduction pathways are also involved in the regulation of hepatic gluconeogenesis, glycogen synthesis and insulin sensitivity. Via TGR5, BA are able to stimulate glucagon-like peptide-1 secretion in the small intestine and energy expenditure in brown adipose tissue and skeletal muscle. Dysregulation of BA transport and impaired BA receptor signaling may contribute to the pathogenesis of non-alcoholic fatty liver disease (NAFLD). Thus, BA transport and BA-controlled nuclear receptors and signaling pathways are promising drug targets for treatment of NAFLD. As such, FXR and/or TGR5 ligands have shown promising results in animal models of NAFLD and clinical pilot studies. Despite being a poor FXR and TGR5 ligand, ursodeoxycholic acid (UDCA) improves hepatic ER stress and insulin sensitivity. Notably, norUDCA, a side chain-shortened homologue of UDCA, improves fatty liver and atherosclerosis in Western diet-fed ApoE(-/-) mice. Collectively, these findings suggest that BA and targeting their receptor/signaling pathways may represent a promising approach to treat NAFLD and closely linked disorders such as obesity, diabetes, dyslipidemia and arteriosclerosis.

Bile Acids and FXR: Novel Targets for Liver Diseases

Role of FXR in Bile Acid and Metabolic Homeostasis in NASH: Pathogenetic Concepts and Therapeutic Opportunities

Development of bile acid activated receptors hybrid molecules for the treatment of inflammatory and metabolic disorders

Farnesoid X receptor modulators 2014-present: a patent review

Recent Advances in the Digestive, Metabolic and Therapeutic Effects of Farnesoid X Receptor and Fibroblast Growth Factor 19: From Cholesterol to Bile Acid Signaling

The regulation of tissue-specific farnesoid X receptor on genes and diseases involved in bile acid homeostasis

FXR: structures, biology, and drug development for NASH and fibrosis diseases

Bile Acid Signaling and Liver Regeneration.

Role of Bile Acids in Dysbiosis and Treatment of Nonalcoholic Fatty Liver Disease

The role of bile acids in regulating glucose and lipid metabolism.

Effect of different bile acids on the intestine through enterohepatic circulation based on FXR

Bile Acids and the Gut Liver Axis

Role of FXR in regulating bile acid homeostasis and relevance for human diseases.

Discovery of farnesoid X receptor and its role in bile acid metabolism

Bile acids and Farnesoid X Receptor in renal pathophysiology

Farnesoid X receptor is an important target for the treatment of disorders of bile acid and fatty acid metabolism in mice with nonalcoholic fatty liver disease combined with cholestasis

Nuclear receptor FXR, bile acids and liver damage: Introducing the progressive familial intrahepatic cholestasis with FXR mutations

Bile Acids as Regulators of Hepatic Lipid and Glucose Metabolism

Farnesoid X Receptor, Bile Acid Metabolism, and Gut Microbiota

Update on FXR Biology: Promising Therapeutic Target?

FXR Friend-ChIPs in the Enterohepatic System